Psychiatry

BMJ

Volumn 323, Issue 7323, 2001, Pages 1228-1231

  Lyons, Declan ^a   Mcloughlin, Declan M ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; CHLORPROMAZINE; CLOZAPINE; GAMMA SECRETASE; NEUROLEPTIC AGENT; OLANZAPINE; PRESENILIN 1; PRESENILIN 2; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ALZHEIMER DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; ENZYME ANALYSIS; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MENTAL DISEASE; NEUROPATHOLOGY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHIATRY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY; TRANSCRANIAL MAGNETIC STIMULATION;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTIPSYCHOTIC AGENTS; ASPARTIC ENDOPEPTIDASES; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER; ELECTROMAGNETIC FIELDS; ENDOPEPTIDASES; HUMANS; MENTAL DISORDERS; STEREOTYPING; STRESS DISORDERS, POST-TRAUMATIC;

EID: 0035944761     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.323.7323.1228     Document Type: Article

References (27)

1. World Health Organization. The world health report 2000—health systems: improving performance. Geneva: WHO, 2000
2. Rosenfield S. Labelling mental illness: the effects of received services and perceived stigma on life satisfaction. American Sociological Review 1997; 62: 660–672.
3. Gureje O, Alem A. Mental health policy development in Africa. Bull World Health Org 2000; 78: 475–482.
4. Crisp AH, Gelder MG, Rix S, Meltzer HI, Rowlands OJ. Stigmatisation of people with mental illnesses. Br J Psychiatry 2000; 177: 4–7.
5. Byrne P. Stigma of mental illness and ways of diminishing it. Adv Psychiat Treat 2000; 6: 65–72.
6. Baker DG, West SA, Nicholson WE, Ekhator NN, Kasckow JW, Hill KK, et al. Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry 1999; 156: 585–588.
7. Liberzon I, Lopez JF, Flagel SB, Vazquez DM, Young EA. Differential regulation of hippocampal glucocorticoid receptors mRNA and fast feedback: relevance to post-traumatic stress disorder. J Neuroendocrinol 1999; 11: 11–17.
8. Newport DJ, Nemeroff CB. Neurobiology of posttraumatic stress disorder. Curr Opin Neurobiol 2000; 10: 211–218.
9. Stein DJ, Seedat S, van der Linden GJH, Zungu-Dirwayi N. Selective serotonin reuptake inhibitors in the treatment of post-traumatic stress disorder: a metaanalysis of randomized controlled trials. Int Clin Psychopharmacol 2000; 15: S31–S39.
10. George MS, Lisanby SH, Sackeim HA. Transcranial magnetic stimulation—applications in neuropsychiatry. Arch Gen Psychiatry 1999; 56: 300–311.
11. Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the international workshop on the safety of repetitive transcranial magnetic stimulation, June 5–7, 1996. Electroencephalogr Clin Neurophysiol 1998; 108: 1–16.
12. Berman RM, Narasimhan M, Sanacora G, Miano AP, Hoffman RE, Hu XS, et al. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biol Psychiatry 2000; 47: 332–337.
13. George MS, Nahas Z, Molloy M, Speer AM, Oliver NC, Li XB, et al. A controlled trial of daily left prefrontal cortex TMS for treating depression. Biol Psychiatry 2000; 48: 962–970.
14. Klein E, Kreinin I, Christyakov A, Koren D, Mecz L, Marmur S, et al. Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression—a double-blind controlled study. Arch Gen Psychiatry 1999; 56: 315–320.
15. Grunhaus L, Dannon PN, Schreiber S, Dolberg OH, Amiaz R, Ziv R, et al. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder. Biol Psychiatry 2000; 47: 314–324.
16. Loo CK, Taylor JL, Gandevia SC, McDarmont BN, Mitchell PB, Sachdev PS. Transcranial magnetic stimulation (TMS) in controlled treatment studies: are some “sham” forms active? Biol Psychiatry 2000; 47: 325–331.
17. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43: 135–145.
18. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156: 990–999.
19. Taylor D, Aitchison K. The pharmaco-economics of atypical antipsychotics. Int J Psychiatr Clin Pract 1999; 3: 237–248.
20. Revicki DA. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophr Res 1999; 35: S101–S109.
21. Essock SM, Frisman LK, Covell NH, Hargreaves WA. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Arch Gen Psychiatry 2000; 57: 987–994.
22. Vassar R, Citron M. Aβ-generating enzymes: recent advances in β- and γ-secretase research. Neuron 2000; 27: 419–422.
23. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735–741.
24. Yan R, Bienkowski MJ, Shuck ME, Miao HY, Tory MC, Pauley AM, et al. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity. Nature 1999; 402: 533–537.
25. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998; 391: 387–390.
26. Zhang ZH, Nadeau P, Song WH, Donoviel D, Yuan ML, Bernstein A, et al. Presenilins are required for γ-secretase cleavage of β-APP and transmembrane cleavage of Notch-1. Nat Cell Biol 2000; 2: 463–465.
27. Wolfe MS, Xia WM, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature 1999; 398: 513–517.